Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | The importance of PTCy as GvHD prophylaxis in hematological malignancies

Rémy Duléry • 15 Apr 2024
EBMT 2024
General Cyclophosphamide

Rémy Duléry, MD, PhD, Saint-Antoine Hospital, Paris, France, briefly discusses the importance of post-transplant cyclophosphamide (PTCy) as prophylaxis for graft-versus-host disease (GvHD), which has significantly improved the outcomes of patients undergoing haploidentical transplant. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rémy Duléry

2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
3:29
PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
Rémy Duléry • 15 Apr 2024

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals